Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics Inc. develops and commercializes precision diagnostic tests focused on oncology, immunotherapy response prediction, and transplant monitoring. The company's product portfolio includes DetermaCNI, a blood-based test designed to detect early cancer treatment progression after a single therapy cycle, and DetermaIO, a gene expression test that assesses tumor microenvironment characteristics to predict immunotherapy response. In the transplant monitoring space, the company offers VitaGraft Kidney and VitaGraft Liver, both blood-based tests that quantify donor-derived cell-free DNA using droplet digital PCR technology, as well as GraftAssure, which measures donor-derived cfDNA concentration using predefined single nucleotide polymorphisms.

Beyond its proprietary test offerings, Insight Molecular Diagnostics provides laboratory services including biomarker discovery, assay design and development, clinical trial support, and custom biomarker testing. The company operates under a collaboration agreement with Bio-Rad Laboratories for developing and commercializing research use only and in vitro diagnostic kitted transplant products utilizing Bio-Rad's ddPCR platform and reagents.

Based in Nashville, Tennessee, the company operates with approximately 46 full-time employees and serves the United States and international markets. The company was incorporated in California in 2009 and changed its name from OncoCyte Corporation to Insight Molecular Diagnostics Inc. in June 2025.